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Introduction: Central nervous system leukemia (CNSL) is
less common in patients with acute myeloid leukemia (AML)
compared to patients with acute lymphoblastic leukemia.
CNSL in AML patients is rare with an incidence less than 5%.
Before high dose cytarabine was incorporated into induction
and consolidation regimens the incidence was higher,
approximately 20%. Because of the low incidence of CNSL in
AML routine evaluation (lumbar puncturewith cerebrospinal
ﬂuid analysis) in patients with no CNS symptoms is not
indicated at diagnosis or relapse. Patients with acute mye-
lomonocytic leukemia, high risk or relapsed acute promye-
locytic leukemia or AMLwith inversion 16 or chromosome 11
abnormalities may have a higher risk of CNSL. High white
blood cell count at diagnosis, elevated LDH and age less than
2 years of age may also increase risk of CNSL. This study was
undertaken to evaluate the incidence of CNSL in patients
with newly diagnosed and relapsed AML.
Methods: 298 adult patients with AML were identiﬁed
through the Mayo Clinic Arizona Cancer Registry between
January 2002 and February 2012. 270 had records available
for retrospective review. Data on AML status (newly diag-
nosed/relapsed disease), cytogenetics, molecular markers,
white blood count at diagnosis and lumbar puncture results
was collected.
Results: 9 (4%) patients underwent lumbar puncture. 8 pa-
tients had CNS symptoms. CNS evaluation in the asymp-
tomatic patient was performed because of high white blood
cell count and myelomonocytic AML at diagnosis. 6 (67%) of
the patients who underwent lumbar puncture were found to
have CNSL. Of the patients with CNSL all were symptomatic,
4 had relapsed or refractory AML (1 post allogeneic he-
matopoietic stem cell transplant (HCT)) and 2 had initial
diagnosis of AML. All patients with CNS leukemia had mye-
lomonocytic AML. No trend in cytogenetic subtype was
noted. Most patients did not have white blood count at
diagnosis or molecular markers available for evaluation.
Discussion: AML can be a difﬁcult disease to cure. Patients
with CNSL have worse outcome and need altered treatment
regimens. CNSL occurring after HCT has an even more dismal
prognosis. Currently there is no indication to evaluate for
CNSL in asymptomatic patients either at diagnosis, relapse or
pre HCT. This small review is notable because all patients
with CNSL had myelomonocytic AML. It has been suggested
previously that these patients are at higher risk for CNSL.
Perhaps the risk for CNSL in thosewithmyelomonocytic AML
has a higher incidence than previously reported and this
patient population should have routine evaluation of the
CNS. Should asymptomatic patients with myelomonocytic
AML undergo lumbar puncture at initial diagnosis, relapse or
pre HCT? Would prophylactic administration of intrathecal
chemotherapy beneﬁt this population? Further prospective
study of the incidence of CNSL in patients with AMLwould be
beneﬁcial.212
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In the German multicenter study group for Adult ALL
(GMALL) high risk (HR) and very high risk (VHR) pts are
candidates for allogeneic stem cell transplantation in CR1
from HLA matched siblings or unrelated donors. The risk
factors are: VHR: Philadelphia chromosome positive ALL
(Ph+ALL); HR of B-lineage ALL (HR-B): leukocytes > 30/nl at
diagnosis and/or delayed CR> 3weeks (other B) or pro B-ALL
and of T-lineage ALL (HR-T): early-T-ALL andmature T-ALL. In
addition standard risk pts were candidates for SCT in case of
molecular failure ormolecular relapse (SR-Mol).106 high risk
ALL pts in CR1 underwent allogeneic SCT between 1995 and
2012 at our center. Median age was 38 years (17 e 67). 70 pts
were male, 36 female. 40/106 pts had Ph+ALL (VHR), 57/106
pts were HR pts (HR-B n ¼ 32: pro-B-ALL n ¼ 15, other B n ¼
17; HR-T n¼ 25: early T n¼ 17, mature T n¼ 4, thymic n¼ 4).
9/106 pts belonged to the SR-Mol group. Stem cell donors
werematched related donors (MRD) in 42 pts and compatible
unrelated donors in 64 pts. The conditioning regimenwas 12
Gy TBICYor VP16 in 86pts, other n¼ 1, and inpts>55 years
8 Gy TBI + FLU(n ¼ 5) or FLU + BU (n ¼ 14).
Results: 60/106 (57 %) pts with high risk ALL transplanted in
CR1 are alive, 46/106 (43 %) pts are dead. The median follow-
up of the surviving pts is 64 months (5 e 172). Causes of
death were leukemia in 16/106 pts (15%) and transplant-
related mortality (TRM) in 30/106 pts (28%). In Ph+ALL 19/40
pts (47 %) are alive in CR (CCR), 12/40 are dead due to TRM
and 9/40 due to leukemia. In HR-B ALL 23/32 pts (71 %) are in
CCR, 8/32 are dead due to TRM and 1/32 due to leukemia. In
HR-T ALL 11/25 pts (44 %) are in CCR, 10/25 died due to TRM
and 4/25 due to leukemia. In SR-Mol 7/9 pts (77 %) are in CCR,
2/9 died due to leukemia. Probability of survival (OS) for all
pts at 96 months is 0.48, probability of disease free survival
(DFS) at 96months is 0.47, probability of TRM at 96months is
0.34. OS was 0.5 for pts with myeloablative conditioning
(MAC) (n¼ 86) and 0.38 for pts with RIC (n¼ 19), n.s. OS was
different for the 4 risk groups: VHR 0.42, HR-B 0.67, HR-T
0.27, SR-Mol 0.74, but not sign. (0.09). DFS: VHR 0.42, HR-B
0.68, HR-T 0.24, SR-Mol 0.76 (0.04) and TRM: VHR 0.34, HR-B
0.26, HR-T 0.58, SR-Mol 0.0 (0.026). In HR-B OS was better for
pro-B-ALL than other B-lineage (0.73.vs. 0.66, resp.). OS was
lower in early-T-ALL (0.24). In mature T-ALL 3/4 pts are dead,
in thymic ALL 1/4 pts.
Conclusion: Long term survival and probably cure can be
reached in high risk ALL pts after allogeneic stem cell
transplantation in CR1. OS in HR-B pts is better than in HR-T-
ALL due to lower relapse rate and lower TRM. If the quality of
remission before allogeneic SCT could be improved in HR-T-
ALL, has to be studied. Allogeneic SCT in SR-Mol show
promising data, though in a small patient cohort. The results
of Ph+ALL can be improved by thyrosine kinase inhibitors in
induction chemotherapy, but was not given regularly in our
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be improved.213
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Introduction: The presence of the FLT3-ITD (internal tan-
dem duplication) mutation in patients with AML is associ-
ated with an adverse prognosis. Even with allogeneic
hematopoietic stem cell transplantation (HSCT), disease
relapse remains the biggest obstacle to success. Sorafenib is
an oral tyrosine kinase inhibitor which has been shown to
inhibit the FLT3 tyrosine kinase and have activity against
FLT3-ITD AML.
Methods: We are conducting a phase I clinical trial of
maintenance sorafenib in patients with FLT3-ITD AML after
HSCT. Any conditioning regimen and any donor source are
allowed. A dose escalation 3+3 cohort design was used to
deﬁne the maximum tolerated dose (MTD) of sorafenib after
HSCT with an additional 10 patients treated at the deﬁned
MTD. Sorafenib was initiated between days 45 and 120 after
HSCT and given continuously for twelve 28-day cycles. All
patients were proven to be in morphological CR after HSCT
and without any active acute graft-vs-host disease prior to
starting sorafenib.
Results: We have thus far enrolled 18 patients (CR1¼12,
CR2¼3, Refractory¼3). 10 patients underwent myeloablative
conditioning and 8 patients received reduced intensity con-
ditioning. Donors included matched related or unrelated
donors (n¼16), cord blood (n¼1), and haploidentical (n¼1).
12 patients were treated in the dose escalation phase: 200
mg BID (n¼3), 400 mg AM / 200 mg PM (n¼3), and 400 mg
BID (n¼6), and 6 patients have been treated so far on the
expansion phase. The MTD was established at 400 mg BID
with only one DLT observed (pericardial effusion) at the 400
mg BID dose level (the highest planned dose). Two patients
experienced early transplant-related mortality - one case of
idiopathic pneumonitis and one case of cirrhosis. Neither of
these deaths was deemed to be related to sorafenib. One
patient has stopped sorafenib after disease relapse and ﬁve
patients have stopped sorafenib due to toxicity (skin, GI,
weight loss, tongue swelling). No cases of grades II-IV acute
GVHD were observed after starting sorafenib and 1-year
cumulative incidence of chronic GVHD is 42% (95% CI 0.14,
0.69), which is similar to our historical controls. In the entire
cohort, there have been only two cases of disease relapse and
both were cases of primary refractory AML prior to HSCT.
Median follow-up for the 14 surviving patients is 10.9
months (range, 2.2-25.8) after transplant. One-year pro-
gression-free survival is 84% (95% CI 0.49, 0.96) and one-yearOS is 93% (95% CI 0.61, 0.99). No patients who underwent
HSCT in CR1 (n¼12) or CR2 (n¼3) have experienced relapse.
Conclusion: Sorafenib appears safe to use after HSCT for
patients with FLT3-ITD AML. Compared to historical results,
our preliminary results suggest promising progression-free
survival with no observed relapses in patients who under-
went HSCT in CR. Maintenance sorafenib after HSCT for
FLT3-ITD AML merits further investigation.214
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The nucleoside analog (NA) clofarabine (Clo) has improved
antileukemic efﬁcacy compared with ﬂudarabine (Flu),
commonly used with IV busulfan (Bu) in pretransplant con-
ditioning. In vitro studies of [Clo+Flu] with Bu in AML cells
showed higher synergistic cytotoxicity compared with
[Clo+Bu] or [Flu+Bu] combination.We studied [CloFlu] with
IV Bu in pretransplant conditioning for ML and MDS.
Methods: Patients were adaptively randomized (AR), based
on day +30- and chimerism-status: Arm I Clo:Flu 10:30 mg/
m2, Arm II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV
Clo only at 40 mg/m2. The NA were/was infused over 60 min
once daily for 4 days, on each day followed by Bu over 3
hours to an average daily AUC of 6,000 mM-min. GVHD-
prophylaxis was tacrolimus and mini-MTX. Recipients of
unrelated (MUD) or one antigen-mismatched related donor
cells received rabbit-ATG infused over 3 days for a total dose
of 4 mg/kg.
Results: 70 patients were treated, M:F 39:31, median age 46
years (6-59). 49 patients had AML, 8 had MDS and 13 had
CML. 29 patients had related donors while 41 had MUDs;
marrow was used in 24, blood progenitor cells in 46. Only 13
of 57 AML/MDS patients were in cytological CR, 44 had active
disease; all CML patients had advanced disease.
All evaluable patients engrafted and there were no sec-
ondary graft failures. Due to the AR, 25 patients were allo-
cated to arms I and II (lower Clo doses), and 45 to Arms III and
IV (higher Clo doses). Safety was acceptable with 100-day
non-relapse mortality of 4%. Grade 2-3 mucositis occurred in
half of the patients and there were no serious hepatic or
neurologic events. The minimum follow-up of surviving
patients was 26 months and there was no difference in
overall or progression-free survival based on CR-status at SCT
or whether patients had a MUD- or related donor graft.
We conclude that (1) [CloFlu] +IV Bu-based conditioning
therapy is safe and efﬁcacious in high-risk patients with ML/
MDS, (2) Clo is sufﬁciently immunosuppressive to be used
in pretransplant conditioning, and (3) the in vitro studies
which showed a superior cytotoxic synergy of [Clo+Flu+Bu]
compared with either [Clo+Bu] or [Flu+Bu] were supported
